Israel does not lack ideas for improving later life. A technology company can develop a new monitoring platform, a hospital can test a digital pathway, a health plan can collaborate with a startup, a municipality can trial a community intervention, and JDC-ESHEL can work with government and local partners to develop new approaches to healthy and independent aging. The more difficult question begins after the pilot appears to work: who will adopt it, who will pay for it, how will it fit existing services, and what evidence is strong enough to justify expansion?
This distinction between invention and implementation is particularly important for aging and long-term care. Israel's innovation ecosystem creates opportunities to develop technology-enabled health and social solutions, while its aging population creates a growing need for approaches that preserve function, strengthen community living, support families and use scarce professional capacity more effectively. The wider system context is explored through the Israel Aging, Long-Term Care & Community Support Knowledge Hub.
Yet an innovation can be technically impressive without solving an operational problem. It can produce encouraging pilot results without being affordable at scale. It can work with highly motivated staff and selected participants while proving much harder to sustain in ordinary practice. It can even reduce workload in one organization while transferring additional responsibility to families, municipalities or another part of the care system.
Israel's next opportunity in aging innovation is therefore not simply to produce more pilots. It is to become better at distinguishing which innovations deserve to progress, designing pilots that answer adoption questions from the outset and building credible routes from experimentation to routine care.
Israel's innovation advantage does not automatically create an implementation advantage
Israel's health-technology environment provides substantial infrastructure for experimentation. The Ministry of Health has developed mechanisms intended to accelerate the development and implementation of digital technologies within health organizations, including support programs and pilot arrangements involving the Israel Innovation Authority. Government policy has also emphasized collaboration between healthcare organizations, academia and industry.
This matters because healthcare innovation rarely develops successfully in isolation from the system expected to use it. Access to clinicians, health organizations, real-world settings and established digital infrastructure can allow developers to test whether a product addresses an actual service need rather than an imagined one.
Israel also has longstanding experience of social innovation around aging. JDC-ESHEL works with the Government of Israel, municipalities, nonprofit organizations and older people to develop and test approaches intended to improve aging outcomes. Earlier initiatives have ranged from technology-enabled social connection to sensor-supported home monitoring and community interventions.
These are important foundations. But the conditions that make Israel effective at generating innovation are not identical to the conditions required for scaling what works.
A startup is typically organized around rapid development, investment milestones and product growth. A health plan or public service has different obligations: continuity, safety, privacy, accessibility, workforce feasibility, financial sustainability and equitable access. Municipal services may operate under different budgets and administrative arrangements again.
Scaling therefore requires translation between different institutional logics. The question is not simply whether innovators and care organizations can collaborate. It is whether they can define success in a way that survives the transition from pilot conditions to routine delivery.
The pilot-to-scale gap begins with the problem being solved
Many innovations enter services through an appealing solution: a platform, sensor, algorithm, app or new service model. Sustainable adoption is more likely when the process begins with the operational problem.
For aging services, that problem might be delayed identification of functional deterioration, preventable falls, difficulty reaching geriatric expertise, caregiver exhaustion, social isolation, medication complexity or inefficient professional workflows.
The distinction is fundamental. A care organization that begins with “we want to use artificial intelligence” is looking for a problem that fits a technology. One that begins with “we are repeatedly identifying deterioration too late among older people living alone” can consider whether AI, remote monitoring, additional community contact or a completely non-digital intervention is the strongest response.
This is particularly important because aging is not a single service market. Older people may interact with health plans, hospitals, the National Insurance Institute, welfare services, municipalities, home-care providers, rehabilitation services, community organizations, foreign caregivers and family members. An innovation designed around one organizational boundary may fail because the real problem crosses several.
The strongest new service models therefore begin by understanding the pathway rather than merely inserting a product into it.
Operational scenario: a promising falls technology meets the real care pathway
A startup develops a home-based technology intended to identify changes in movement that may indicate increasing falls risk among older people. A health organization agrees to test it with a relatively small group of participants.
The initial pilot looks encouraging. The technology detects changes that would not otherwise have been visible between routine contacts, and both participants and clinicians report that the information could be useful.
The scaling discussion exposes harder questions.
Who reviews an alert at 10 a.m. on a normal working day? Is the appropriate response a telephone call, a physiotherapy referral, a medication review or a home assessment? What happens if the alert identifies environmental risks that sit outside the health plan's direct responsibility? Does the technology work equally well for a person living alone and somebody supported by a live-in caregiver? How many alerts can a community team absorb before the system creates more work than it prevents?
The pilot is redesigned to examine the complete pathway. Alert volume, professional response time, subsequent intervention, falls, functional outcomes and participant experience are measured. The project also records cases in which the technology identifies a problem but the service cannot respond quickly enough.
The result is more valuable than a simple demonstration that the sensor works. Decision-makers can now assess whether the innovation improves an existing falls pathway and what workforce capacity would be required to scale it.
Evidence for adoption is different from evidence that a product functions
A pilot can answer several different questions, and they should not be confused.
Technical validation asks whether the technology performs as intended. Clinical or service evaluation asks whether its use changes relevant outcomes. Implementation evaluation asks whether staff and users can incorporate it into real practice. Economic evaluation asks whether the benefits justify the resources required.
A scalable aging innovation may therefore need evidence across several dimensions:
- effectiveness for the intended older population;
- safety and unintended consequences;
- acceptability to older people, families and staff;
- workflow and workforce implications;
- equity of access and differential outcomes;
- costs, avoided activity and wider system impact; and
- the feasibility of maintaining performance beyond the pilot.
Israel's Ministry of Health has explicitly recognized this implementation challenge in its digital-health guidance. Broad implementation requires organizations to examine effectiveness, train staff and invest resources even during feasibility testing. Its guidance on digital-health technology evaluation also recognizes that collaboration with startups creates particular operational considerations because young companies often work with limited resources and rapid commercialization timelines.
This makes pilot evaluation and learning loops central to scale rather than an academic exercise added after deployment.
Organizations examining similar innovations can use the Quality Improvement Action Plan Builder to translate pilot findings into defined actions, responsibilities and follow-through. It is not an Israeli technology-assessment framework, but it can help prevent evaluation findings from remaining disconnected from implementation decisions.
Older people need to be participants in innovation, not simply test populations
Aging technology is particularly vulnerable to design assumptions.
A developer may consider an interface intuitive because it works well for the development team. An older person living with reduced vision, tremor, hearing loss or mild cognitive impairment may experience it differently. A service may assume that a family member can help with setup even though the person lives alone. A Hebrew-language interface may not meet the needs of every population expected to use it.
These are not peripheral usability issues. They determine whether the innovation can scale equitably.
Co-design should therefore influence the product before the final pilot, and participation should include people whose needs make implementation more difficult rather than only confident early adopters.
Older people can help test whether the intervention solves a problem they actually value, whether consent is understandable, whether monitoring feels supportive or intrusive and what outcomes matter from their perspective.
For aging services, that may change the definition of success. A technology designed to reduce professional visits might appear efficient to an organization while being experienced by an isolated older person as the removal of an important source of human contact.
Innovation should improve life, not merely optimize transactions.
Procurement is where many pilots encounter a different reality
A pilot can be established through a grant, innovation program, research partnership or time-limited agreement. Routine adoption requires a sustainable purchasing or funding mechanism.
That transition can be difficult because the organization that benefits from an innovation may not be the organization expected to pay for it.
Consider an intervention that helps older people maintain mobility and reduces falls. Its benefits may include fewer emergency visits, less family caregiving, delayed functional dependency and reduced need for long-term support. Those effects potentially matter to health plans, the National Insurance Institute, municipalities, families and the wider public system, but they do not necessarily appear within one budget.
The same problem arises when a technology saves hospital capacity but requires additional community staff, or when a municipal social intervention improves wellbeing while its measurable financial benefit appears elsewhere.
Scaling decisions therefore need to identify both the value created and where that value accrues.
This is one reason why innovation funding cannot permanently substitute for mainstream funding. Grants can help absorb experimentation risk. They cannot provide indefinite operating revenue for a service that has never established who will purchase it once the demonstration ends.
A credible scale plan should therefore begin developing its post-pilot financial route before the pilot is complete. That may involve health-plan adoption, incorporation within an existing service, public procurement, municipal funding, inclusion within an eligible benefit or another sustainable purchasing mechanism depending on the intervention.
The wider relationship between funding and payment models becomes part of innovation design rather than a commercial conversation deferred until the end.
Operational scenario: a social innovation succeeds but has no obvious budget owner
A municipality and nonprofit organization test a program combining digital group activity, volunteer contact and structured community participation for older people at risk of isolation. Participation is strong, older people report greater connection and some families describe improved confidence that relatives are engaged during the week.
The pilot grant is approaching its end.
The problem is not whether people liked the program. It is that no single organization owns all of its outcomes. The municipality values community participation. Health services may benefit if improved connection supports mental and physical wellbeing. Families experience reduced anxiety. The nonprofit has developed operational expertise but cannot finance permanent delivery itself.
Rather than treating the final evaluation as a celebration of activity, the partners examine which population benefits most, what elements of the model are essential, what each participant costs and which outcomes can reasonably be attributed to the program.
They also distinguish between the technology platform and the human operating model. The digital component enables reach, but volunteers, facilitation and referral relationships generate much of the value.
The scale proposal is consequently redesigned around a defined population and service pathway rather than a general request to continue the pilot. The experience demonstrates a recurring principle in social innovation: sustainability often depends on making responsibility for the outcome as clear as enthusiasm for the intervention.
Scaling requires an operating model, not simply more licenses
Technology companies often scale by adding customers. Care systems scale by changing practice.
Those are not the same process.
If an innovation is introduced across several clinics, municipalities or home-care services, staff need to understand who uses it, at what point in the pathway, what happens to the information it produces and how exceptions are managed. Training has to extend beyond the small group of enthusiasts involved in the original pilot.
Implementation therefore needs to answer practical questions about referral, eligibility, onboarding, consent, data access, technical support, escalation, supervision and discontinuation.
The more complex the intervention, the more important implementation fidelity becomes. Local adaptation is often necessary, but removing essential components can produce a scaled version that shares the pilot's name without reproducing its results.
Conversely, insisting that every location reproduce the pilot exactly can make adoption impossible where staffing, population needs or local infrastructure differ.
Scale therefore requires clarity about the intervention's core components and the elements that can legitimately adapt.
This is where practice fidelity and model adherence become useful concepts beyond traditional clinical programs. Leaders need to know whether disappointing results reflect an ineffective innovation or an implementation model that has drifted away from the intervention that originally produced benefit.
Workforce adoption is often the hidden determinant of success
Care innovation is sometimes framed as if technology arrives and efficiency follows. In practice, staff mediate much of its value.
A nurse may need to review information that was not previously available. A physiotherapist may receive digitally generated referrals. A social worker may need to help an older person navigate a new service. Home-care workers may become responsible for supporting a device. Administrative staff may manage onboarding and troubleshooting.
These changes can improve productivity, but they can also shift workload.
A system that automatically identifies hundreds of people at possible risk has not necessarily created capacity if professionals then have to assess hundreds of low-value alerts. A digital intake process may save administrative time for one team while creating additional support calls elsewhere.
Workforce evaluation should therefore examine total work rather than only the task the technology was designed to remove.
It should also examine skills. Digital innovation may require staff to interpret data, explain automated recommendations, recognize technology failure and discuss privacy or consent with older people. Supervisors need enough understanding to assure practice rather than assuming that technical expertise sits entirely with the supplier.
The opportunity lies in workforce innovation and role redesign, not indiscriminate substitution of technology for care workers and professionals.
Health innovation has a stronger institutional route than some social-care innovation
Israel's healthcare system offers significant assets for innovation adoption. Four health plans organize healthcare for the population under the National Health Insurance framework, major hospitals and health organizations have developed innovation capabilities, and national initiatives have created mechanisms for collaboration between the public health system and technology sector.
The Ministry of Health's innovation agenda has addressed regulation, technology implementation, economic efficiency, human capital, financing, data and collaboration between healthcare organizations, academia and industry.
In July 2026, the Ministry of Health and Israel Innovation Authority announced the first companies selected for a new regulatory sandbox for highly autonomous artificial intelligence in healthcare. The program combines real-world testing with active regulatory learning rather than treating regulation as something considered only after development.
That is significant for the innovation system, although it should not be confused with evidence that autonomous AI is already routine across Israeli aging services. The sandbox is an emerging regulatory mechanism for selected technologies, not proof of nationwide implementation.
Social and long-term care innovation can face a more fragmented route. The relevant actor may be the National Insurance Institute, Ministry of Welfare and Social Affairs, Ministry of Health, a municipality, a provider, a voluntary organization or a combination of them. Families and privately employed caregivers may also be integral to delivery.
The result is that an innovation crossing health and social boundaries may have a persuasive use case but no single adoption pathway.
Regulation can enable experimentation without lowering the standard of protection
Innovation policy sometimes presents regulation as a barrier to speed. For services affecting older people, the stronger approach is to make regulatory learning part of responsible development.
A regulatory sandbox illustrates this principle. Selected technologies can be examined within a supervised environment in which developers, health organizations and regulators learn about risks and requirements while evidence is generated.
The model is particularly relevant to technologies whose behavior cannot be assessed adequately through conventional static approval assumptions, including more autonomous artificial-intelligence systems.
For aging services, regulatory questions may extend beyond medical-device status. Privacy, consent, cybersecurity, accessibility, professional responsibility and discrimination can all affect implementation.
An algorithm may perform well overall while working less reliably for particular groups. A monitoring system may improve safety while collecting more information from the home than is proportionate. An automated recommendation may save professional time while making responsibility unclear when the recommendation is wrong.
Responsible innovation therefore connects technological opportunity with trust, transparency and ethical data use.
Organizations evaluating similar developments can use the Digital Transformation, AI and Cybersecurity Readiness Assessment to examine whether governance, workforce capability and infrastructure are keeping pace with technological ambition. It does not replace Israeli regulation or technology assessment, but it provides a structured way to test organizational readiness before scale magnifies unresolved weaknesses.
Operational scenario: an AI pilot performs well but cannot yet become routine care
A health organization pilots an AI-enabled tool intended to identify older people whose clinical patterns suggest an increased risk of deterioration. Retrospective validation is strong and the initial live pilot demonstrates that the system can identify some people earlier than existing processes.
A superficial interpretation would recommend rapid expansion.
The implementation review identifies unresolved questions. Clinicians do not always understand why a person has been flagged. Some alerts duplicate risks already known to the primary-care team. Performance varies between population groups, and there is uncertainty about how responsibility should be recorded when a clinician chooses not to follow the algorithm's recommendation.
The organization therefore does not treat pilot success as automatic authorization for scale.
The next phase tests explainability, alert usefulness, differential performance and professional response. Clinical governance defines where human judgment remains decisive and how disagreements with the system are documented. Older people are given understandable information about how the technology contributes to their care.
The delay is not evidence that innovation has failed. It is evidence that scale introduces requirements that technical validation alone cannot resolve.
A responsible innovation system creates space for that learning before exposure becomes much larger.
Scale should be judged by outcomes, not geographical spread
An intervention operating in twenty locations is not necessarily more successful than one operating in five.
Expansion can dilute quality, reach populations for whom the intervention is less effective or create operating costs that were invisible during the pilot. A service can scale its footprint while weakening its impact.
Israel's work on optimal aging provides a useful counterweight to activity-based thinking. JDC-ESHEL and public partners developed shared indicators around health and functionality, meaning and economic resilience, with the Government of Israel adopting an optimal-aging indicators framework in 2021.
The significance for innovation is methodological. A new service should ultimately connect to outcomes that matter for aging rather than treating deployment itself as the outcome.
For different innovations, relevant evidence may include maintained function, reduced loneliness, improved caregiver capacity, safer medication use, delayed dependency, improved access, greater participation or more appropriate healthcare utilization.
Organizations can use the Quality Dashboard Builder to structure comparable operational and outcome measures when evaluating innovation portfolios. It does not reproduce Israel's national aging indicators, but it reinforces the principle that leaders need a coherent view of implementation, quality and impact rather than a count of projects launched.
Scaling also means deciding what to stop
A mature innovation ecosystem does not scale every promising project.
Some pilots should end because the intervention does not produce sufficient benefit. Others may work but cost too much. Some may duplicate a capability already available elsewhere. A technology may become obsolete before implementation is complete. Another may prove valuable for a narrower population than originally intended.
Stopping is therefore part of innovation governance.
The danger is that institutional enthusiasm, sunk cost or relationships with project partners make discontinuation harder than launching the pilot was. Innovation programs can accumulate layers of small initiatives because nobody has established an explicit decision point at which evidence is compared with the original case for investment.
A stronger portfolio has defined gates: continue, adapt, scale, integrate, pause or stop.
Those decisions should consider not only whether an intervention generated statistically or operationally positive results, but whether it remains strategically relevant and whether another intervention could produce greater value from the same workforce and funding.
This introduces the discipline of cost versus outcomes into innovation management without reducing every decision to short-term financial savings.
Operational scenario: national expansion reveals an equity problem
A digital support service is successful in an urban pilot involving relatively confident technology users. Participants report easier access to advice and staff find that some routine contacts can be handled more efficiently.
Expansion begins across a wider population.
Uptake is substantially lower among some older adults who have limited digital skills, require a different language, have sensory impairment or depend on relatives to manage online processes. In peripheral areas, connectivity and local support capacity also affect the experience.
The original outcome data remain accurate for the pilot population, but they are no longer sufficient to describe the scaled service.
The organization responds by adding assisted onboarding, telephone alternatives, accessibility improvements and targeted community partnerships. It starts reporting uptake, completion and outcomes by relevant population characteristics rather than presenting one aggregate figure.
The intervention becomes more expensive to operate than the original pilot suggested, but it also becomes more credible as a population service.
This is a central lesson of scale: variation that was invisible in a small demonstration becomes operationally significant when an innovation reaches people with different capabilities, languages, living circumstances and support networks.
Governance has to follow innovation across organizational boundaries
Aging innovations frequently cross boundaries that ordinary governance arrangements were not designed around.
A technology company may own the product, a health plan may hold clinical responsibility, a municipality may support implementation, a nonprofit may recruit participants and family members may provide practical assistance in the home.
When something goes wrong, contractual complexity cannot substitute for clear responsibility.
Governance therefore needs to establish who owns service outcomes, technology performance, privacy, cybersecurity, incident response, workforce competence and continuity if the supplier fails or withdraws.
Decision-makers also need visibility of aggregate performance. A pilot should not sit indefinitely within an innovation team if it has begun affecting ordinary care. Once an intervention changes real service delivery, its risks and outcomes need to enter the organization's normal assurance structures.
This is particularly important when pilots proliferate. Senior leaders need to know which innovations are live, which populations are affected, what evidence supports them, what unresolved risks remain and which projects are approaching a scale decision.
The Governance Maturity Assessment can help organizations considering similar questions examine decision rights, risk ownership and assurance. Its relevance is the governance discipline rather than any claim to represent Israeli regulatory requirements.
Israel can treat the care system itself as innovation infrastructure
The most powerful innovation ecosystems do more than provide test sites. They create repeatable routes through which genuine service problems are identified, solutions are tested, evidence is generated and successful models are adopted.
For Israel, this could mean strengthening the connection between national aging priorities and innovation demand.
Instead of innovators primarily approaching services with finished solutions, health plans, ministries, municipalities, the National Insurance Institute, providers and organizations working with older people can define priority problems that require new approaches.
Those challenges might include maintaining function after hospitalization, reducing caregiver burden, supporting older people in peripheral areas, improving dementia-capable community support or extending scarce professional expertise.
Innovation can then be assessed against a defined system requirement.
This approach changes procurement too. Rather than asking only which product should be purchased, public and care organizations can ask what outcome they are trying to achieve and which combination of service redesign, technology and workforce change is required.
It also reduces the risk that technology-enabled care becomes synonymous with buying technology. In many successful models, technology is one component of a redesigned human service.
From individual pilots to an innovation learning system
One of the largest unrealized benefits of repeated experimentation is collective learning.
If every hospital, health plan, municipality or organization runs pilots independently, similar implementation problems may be rediscovered repeatedly. One project learns that onboarding is difficult. Another discovers that staff training was underestimated. A third finds that procurement takes longer than the startup can sustain. Those lessons have system value beyond the individual project.
A stronger innovation architecture captures not only which pilots succeeded but why implementation succeeded or failed.
That evidence can include time from approval to deployment, recruitment rates, staff adoption, technology failures, participant withdrawal, implementation costs, regulatory issues, procurement barriers and reasons projects were discontinued.
Aggregating such information would help future programs design better pilots and allow policymakers to identify recurring structural barriers rather than treating each failed implementation as an isolated project problem.
This connects innovation with organizational culture and learning systems. An innovation ecosystem becomes more valuable when unsuccessful experiments improve the next generation of decisions rather than disappearing from view.
The future opportunity is selective scale, not permanent experimentation
Israel's technology ecosystem makes continued experimentation likely. Population aging makes disciplined adoption increasingly important.
As demand grows, health and long-term care systems cannot indefinitely maintain parallel portfolios of pilots that depend on temporary funding and exceptional staff effort. Innovation needs to contribute to sustainable capacity.
That means becoming more selective.
Some technologies may automate administrative work and release professional time. Others may allow specialist expertise to reach more people. Home-based models may reduce avoidable institutional use. Predictive tools may support earlier intervention. Social innovations may strengthen participation and reduce isolation without requiring sophisticated technology at all.
The common requirement is a credible pathway from problem to evidence to adoption.
Future innovation policy can strengthen that pathway by aligning pilot design with procurement, funding, workforce and regulatory questions from the beginning. It can also make equity and older people's experience core adoption criteria rather than matters addressed after scale.
Where uncertainty remains high, scenario modelling can help leaders examine the consequences of alternative implementation choices before committing scarce capacity. The Digital Twin Scenario Modeler, for example, provides organizations examining analogous service questions with a way to test assumptions about workforce, capacity and stability. It is not a predictive model of Israel's aging system, but it illustrates the value of testing scale assumptions before they become operational commitments.
What other countries can learn from Israel's innovation challenge
Israel's innovation environment is shaped by characteristics that cannot simply be reproduced elsewhere. Its technology sector, health-plan structure, digital-health history, government innovation infrastructure and relationships between public organizations and industry create a particular institutional setting.
The transferable lesson is therefore not that other aging systems should attempt to become copies of Israel's startup ecosystem.
It is that innovation capacity and implementation capacity are different assets.
Countries with fewer technology companies can still become excellent adopters by defining problems clearly, designing strong evaluations, creating credible purchasing routes and learning systematically from implementation. Conversely, a country can generate large numbers of inventions without converting them into meaningful population benefit.
Israel's experience also highlights the importance of bringing regulation into innovation early, involving service organizations in development and connecting technology policy with real public-system challenges.
For aging services in particular, another lesson is essential: innovation should be judged by what changes for older people. Commercial growth, investment and technical sophistication may be important to an innovation ecosystem, but they are not substitutes for independence, function, safety, connection, caregiver sustainability and quality of life.
Conclusion
Israel has substantial assets for innovation in aging services: a sophisticated technology sector, digitally mature healthcare organizations, public mechanisms for experimentation, research capability and longstanding partnerships developing new responses to the needs of older people. Those strengths create an unusually fertile environment for pilots.
The next strategic challenge is to make scale more deliberate. A successful demonstration needs to become an implementable service model with clear ownership, sustainable funding, workforce capacity, appropriate regulation, measurable outcomes and an operating model that survives outside exceptional pilot conditions. Equally, systems need the confidence to stop innovations that do not justify wider adoption.
For older people and families, this distinction matters profoundly. They do not experience innovation as an ecosystem, investment category or technology pipeline. They experience whether support becomes easier to access, whether deterioration is identified earlier, whether independence lasts longer, whether caregivers receive meaningful help and whether new technologies preserve rather than diminish autonomy and human connection.
Israel's strongest opportunity is therefore not to maximize the number of aging innovations it produces. It is to build a disciplined bridge between invention and everyday care: identifying important problems, testing solutions rigorously, learning openly, scaling selectively and embedding successful models into the institutions that will sustain them. That is how an innovation ecosystem becomes a long-term care-system asset rather than a permanent collection of promising pilots.